{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:08:44Z","timestamp":1783940924963,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The aim of this trial was to assess whether dietary counseling together with supplemental fiber improves gastrointestinal (GI) tolerability during dose escalation with controlled-release orlistat\u2013acarbose (EMP16) in adults who had reported prior GI side effects. In this randomized, single-blind, phase 2 pilot trial, adults with obesity (BMI\u2009\u2265\u200930 kg\/m\u00b2 or \u2265\u200927 kg\/m\u00b2 with risk factors) and prior GI problems to conventional orlistat or EMP16 were randomized 1:2 to EMP16 plus psyllium-based fiber or conventional orlistat plus maltodextrin placebo for 39 days, both with diet counseling. The primary endpoint was the composite gastrointestinal tolerability events (GITE) area-under-the-curve (AUC) score (diarrhea, oily spotting, flatulence with discharge, fecal incontinence) from daily electronic diaries. Additional endpoints included investigator-assessed GI adverse events, anthropometry, and cardiometabolic markers. Thirty-six participants completed treatment. GI event rates were much lower than expected in both arms, and GITE AUC differences were not statistically significant. Total events and time to first GI event favored EMP16 plus fiber. Greater relative weight loss occurred with EMP16 plus fiber vs. conventional orlistat plus placebo (p\u2009=\u20090.026), with similar\u2009~\u200910% LDL-cholesterol reductions. Dietary counseling during treatment with EMP16 or conventional orlistat may mitigate GI side effects in adults with prior GI side effects and co\u2011administration of fiber might further enhance tolerability and efficacy.<\/jats:p>","DOI":"10.1038\/s41598-026-62003-6","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:36:18Z","timestamp":1783938978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of dietary counseling and dietary fiber on tolerability during weight management with EMP16 and conventional orlistat: a single-blind randomized pilot trial"],"prefix":"10.1038","volume":"16","author":[{"given":"Ulf","family":"Holmb\u00e4ck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Grud\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Kuusk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Litorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joakim","family":"Englund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvid","family":"S\u00f6derh\u00e4ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6ran","family":"Alderborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Forslund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"62003_CR1","doi-asserted-by":"publisher","first-page":"101098","DOI":"10.1016\/j.lanepe.2024.101098","volume":"47","author":"A Novikoff","year":"2024","unstructured":"Novikoff, A., Grandl, G., Liu, X. & T, D. M. Why are we still in need for novel anti-obesity medications? Lancet Reg. Health Eur. 47, 101098. https:\/\/doi.org\/10.1016\/j.lanepe.2024.101098 (2024).","journal-title":"Lancet Reg. Health Eur."},{"key":"62003_CR2","doi-asserted-by":"publisher","first-page":"e2457349","DOI":"10.1001\/jamanetworkopen.2024.57349","volume":"8","author":"PJ Rodriguez","year":"2025","unstructured":"Rodriguez, P. J. et al. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Netw. Open. 8, e2457349. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.57349 (2025).","journal-title":"JAMA Netw. Open."},{"key":"62003_CR3","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1002\/oby.23557","volume":"30","author":"U Holmback","year":"2022","unstructured":"Holmback, U. et al. Effects of a novel weight-loss combination product containing orlistat and acarbose on obesity: A randomized, placebo-controlled trial. Obes. (Silver Spring). 30, 2222\u20132232. https:\/\/doi.org\/10.1002\/oby.23557 (2022).","journal-title":"Obes. (Silver Spring)"},{"key":"62003_CR4","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/cpdd.1503","volume":"14","author":"S Gruden","year":"2025","unstructured":"Gruden, S. et al. A Comparative Analysis of the Pharmacodynamic and Pharmacokinetic Properties of 2 Controlled-Release Formulations Versus a Marketed Orlistat Product. Clin. Pharmacol. Drug Dev. 14, 304\u2013310. https:\/\/doi.org\/10.1002\/cpdd.1503 (2025).","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"62003_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2337\/diacare.27.1.155","volume":"27","author":"JS Torgerson","year":"2004","unstructured":"Torgerson, J. S., Hauptman, J., Boldrin, M. N. & Sjostrom, L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 27, 155\u2013161. https:\/\/doi.org\/10.2337\/diacare.27.1.155 (2004).","journal-title":"Diabetes Care"},{"key":"62003_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2165\/00044011-200222030-00001","volume":"22","author":"H Laube","year":"2002","unstructured":"Laube, H. & Acarbose An Update of Its Therapeutic Use in Diabetes Treatment. Clin. Drug Investig. 22, 141\u2013156. https:\/\/doi.org\/10.2165\/00044011-200222030-00001 (2002).","journal-title":"Clin. Drug Investig."},{"key":"62003_CR7","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/sj.ijo.0801645","volume":"25","author":"H Cavaliere","year":"2001","unstructured":"Cavaliere, H., Floriano, I. & Medeiros-Neto, G. Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid). Int. J. Obes. Relat. Metabolic Disorders: J. Int. Association Study Obes. 25, 1095\u20131099. https:\/\/doi.org\/10.1038\/sj.ijo.0801645 (2001).","journal-title":"Int. J. Obes. Relat. Metabolic Disorders: J. Int. Association Study Obes."},{"key":"62003_CR8","unstructured":"Council, N. Nordic Nutrition Recommendations 2023. (2023)."},{"key":"62003_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1023\/a:1008841022998","volume":"7","author":"DA Revicki","year":"1998","unstructured":"Revicki, D. A., Wood, M., Wiklund, I. & Crawley, J. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual. Life Research: Int. J. Qual. Life Aspects Treat. Care Rehabilitation. 7, 75\u201383. https:\/\/doi.org\/10.1023\/a:1008841022998 (1998).","journal-title":"Qual. Life Research: Int. J. Qual. Life Aspects Treat. Care Rehabilitation"},{"key":"62003_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni, G. et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 6, 33. https:\/\/doi.org\/10.1186\/1471-230X-6-33 (2006).","journal-title":"BMC Gastroenterol."},{"key":"62003_CR11","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1002\/oby.24369","volume":"33","author":"U Holmback","year":"2025","unstructured":"Holmback, U. et al. The Supportive Effect of Acarbose to Orlistat in Weight Management-A Randomized, Double-Blind, Multiarm Phase 2 Trial. Obes. (Silver Spring). 33, 1855\u20131864. https:\/\/doi.org\/10.1002\/oby.24369 (2025).","journal-title":"Obes. (Silver Spring)"},{"key":"62003_CR12","doi-asserted-by":"publisher","DOI":"10.2337\/doci25-0008","author":"KA Gudzune","year":"2026","unstructured":"Gudzune, K. A. et al. Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity. Diabetes Obes. Cardiometabolic CARE. https:\/\/doi.org\/10.2337\/doci25-0008 (2026).","journal-title":"Diabetes Obes. Cardiometabolic CARE"},{"key":"62003_CR13","unstructured":"Pedersen, S. D. et al. Canadian Adult Obesity Clinical Practice Guideline: Pharmacotherapy for Obesity Management in Adults, <>ca\/healthcareprofessionals\/adult-clinical-practiceguideline (2025)."},{"key":"62003_CR14","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/sj.ijo.0801814","volume":"25","author":"LVG Group","year":"2001","unstructured":"Group, L. V. G. et al. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int. J. Obes. 25, 1713\u20131721. https:\/\/doi.org\/10.1038\/sj.ijo.0801814 (2001).","journal-title":"Int. J. Obes."},{"key":"62003_CR15","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1345\/aph.19412","volume":"35","author":"KH Lucas","year":"2001","unstructured":"Lucas, K. H. & Kaplan-Machlis, B. Orlistat\u2013a novel weight loss therapy. Annals Pharmacotherapy. 35, 314\u2013328. https:\/\/doi.org\/10.1345\/aph.19412 (2001).","journal-title":"Annals Pharmacotherapy"},{"key":"62003_CR16","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1007\/s10620-005-2900-6","volume":"50","author":"M Fox","year":"2005","unstructured":"Fox, M. et al. The Effects of Loperamide on Continence Problems and Anorectal Function in Obese Subjects Taking Orlistat. Dig. Dis. Sci. 50, 1576\u20131583. https:\/\/doi.org\/10.1007\/s10620-005-2900-6 (2005).","journal-title":"Dig. Dis. Sci."},{"key":"62003_CR17","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1185\/030079907X182176","volume":"23","author":"SB Hanauer","year":"2007","unstructured":"Hanauer, S. B., DuPont, H. L., Cooper, K. M. & Laudadio, C. Randomized, double-blind, placebo-controlled clinical trial of loperamide plus simethicone versus loperamide alone and simethicone alone in the treatment of acute diarrhea with gas-related abdominal discomfort. Curr. Med. Res. Opin. 23, 1033\u20131043. https:\/\/doi.org\/10.1185\/030079907X182176 (2007).","journal-title":"Curr. Med. Res. Opin."},{"key":"62003_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12986-017-0164-8","volume":"14","author":"M Kristensen","year":"2017","unstructured":"Kristensen, M., Juul, S. R., S\u00f8rensen, K. V., Lorenzen, J. K. & Astrup, A. Supplementation with dairy calcium and\/or flaxseed fibers in conjunction with orlistat augments fecal fat excretion without altering ratings of gastrointestinal comfort. Nutr. Metabolism. 14, 13. https:\/\/doi.org\/10.1186\/s12986-017-0164-8 (2017).","journal-title":"Nutr. Metabolism"},{"key":"62003_CR19","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.2337\/diacare.21.10.1612","volume":"21","author":"TMS Wolever","year":"1998","unstructured":"Wolever, T. M. S. et al. No Relationship Between Carbohydrate Intake and Effect of Acarbose on HbA1c or Gastrointestinal Symptoms in Type 2 Diabetic Subjects Consuming 30\u201360% of Energy From Carbohydrate. Diabetes Care. 21, 1612\u20131618. https:\/\/doi.org\/10.2337\/diacare.21.10.1612 (1998).","journal-title":"Diabetes Care"},{"key":"62003_CR20","first-page":"78","volume":"18","author":"F Arungarinathan","year":"2011","unstructured":"Arungarinathan, F., McKay, G. A. & Fisher, M. Drugs for diabetes: part 4 acarbose. Br. J. Cardiol. 18, 78\u201381 (2011).","journal-title":"Br. J. Cardiol."},{"key":"62003_CR21","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1046\/j.1365-2036.2001.00982.x","volume":"15","author":"LR Schiller","year":"2001","unstructured":"Schiller, L. R. Review article: the therapy of constipation. Aliment. Pharmacol. Ther. 15, 749\u2013763. https:\/\/doi.org\/10.1046\/j.1365-2036.2001.00982.x (2001).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"62003_CR22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/osp4.405","volume":"6","author":"U Holmb\u00e4ck","year":"2020","unstructured":"Holmb\u00e4ck, U. et al. Effects of a novel combination of orlistat and acarbose on tolerability, appetite, and glucose metabolism in persons with obesity. Obes. Sci. Pract. 6, 313\u2013323. https:\/\/doi.org\/10.1002\/osp4.405 (2020).","journal-title":"Obes. Sci. Pract."},{"key":"62003_CR23","doi-asserted-by":"publisher","first-page":"2197837","DOI":"10.1080\/19490976.2023.2197837","volume":"15","author":"H Lai","year":"2023","unstructured":"Lai, H. et al. Effects of dietary fibers or probiotics on functional constipation symptoms and roles of gut microbiota: a double-blinded randomized placebo trial. Gut Microbes. 15, 2197837. https:\/\/doi.org\/10.1080\/19490976.2023.2197837 (2023).","journal-title":"Gut Microbes"},{"key":"62003_CR24","doi-asserted-by":"publisher","first-page":"e13400","DOI":"10.1111\/nmo.13400","volume":"30","author":"G Major","year":"2018","unstructured":"Major, G. et al. Demonstration of differences in colonic volumes, transit, chyme consistency, and response to psyllium between healthy and constipated subjects using magnetic resonance imaging. Neurogastroenterology Motil. 30, e13400. https:\/\/doi.org\/10.1111\/nmo.13400 (2018).","journal-title":"Neurogastroenterology Motil."},{"key":"62003_CR25","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jcmgh.2018.09.002","volume":"7","author":"F Laudisi","year":"2019","unstructured":"Laudisi, F. et al. The Food Additive Maltodextrin Promotes Endoplasmic Reticulum Stress\u2013Driven Mucus Depletion and Exacerbates Intestinal Inflammation. Cell. Mol. Gastroenterol. Hepatol. 7, 457\u2013473. https:\/\/doi.org\/10.1016\/j.jcmgh.2018.09.002 (2019).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"62003_CR26","unstructured":"Gao, H. et al. Rhubarb extract rebuilding the mucus homeostasis and regulating mucin-associated flora to relieve constipation."},{"key":"62003_CR27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1177\/0272989X03251245","volume":"23","author":"EJ Frew","year":"2003","unstructured":"Frew, E. J., Whynes, D. K. & Wolstenholme, J. L. Eliciting willingness to pay: comparing closed-ended with open-ended and payment scale formats. Med. Decis. Mak. 23, 150\u2013159. https:\/\/doi.org\/10.1177\/0272989X03251245 (2003).","journal-title":"Med. Decis. Mak."},{"key":"62003_CR28","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1006\/jmla.2002.2864","volume":"46","author":"AP Yonelinas","year":"2002","unstructured":"Yonelinas, A. P. The Nature of Recollection and Familiarity: A Review of 30 Years of Research. J. Mem. Lang. 46, 441\u2013517. https:\/\/doi.org\/10.1006\/jmla.2002.2864 (2002).","journal-title":"J. Mem. Lang."},{"key":"62003_CR29","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff, A. M. et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl. J. Med. 389, 2221\u20132232. https:\/\/doi.org\/10.1056\/NEJMoa2307563 (2023).","journal-title":"N Engl. J. Med."},{"key":"62003_CR30","doi-asserted-by":"publisher","first-page":"348","DOI":"10.7570\/jomes24008","volume":"33","author":"MU Mahar","year":"2024","unstructured":"Mahar, M. U. et al. The Effects of Tirzepatide on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J. Obes. Metabolic Syndrome. 33, 348\u2013359. https:\/\/doi.org\/10.7570\/jomes24008 (2024).","journal-title":"J. Obes. Metabolic Syndrome"},{"key":"62003_CR31","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1093\/ajcn\/80.6.1461","volume":"80","author":"B Hutton","year":"2004","unstructured":"Hutton, B. & Fergusson, D. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am. J. Clin. Nutr. 80, 1461\u20131468. https:\/\/doi.org\/10.1093\/ajcn\/80.6.1461 (2004).","journal-title":"Am. J. Clin. Nutr."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62003-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62003-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62003-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:01:18Z","timestamp":1783940478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62003-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["62003"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-62003-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ulf Holmb\u00e4ck, Stefan Grud\u00e9n, Arvid S\u00f6derh\u00e4ll, G\u00f6ran Alderborn and Anders Forslund have equity interests in Empros Pharma AB and have acted as employees or consultants for the company. Ulf Holmb\u00e4ck, Stefan Grud\u00e9n, G\u00f6ran Alderborn and Anders Forslund hold the patent for the studied anti-obesity medication. Sandra Kuusk, Helena Litorp and Joakim Englund are employed at or work as consultants for Clinical Trial Consultants AB but declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21835"}}